Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,018.39 -17.30 (-0.34%) Dow
37,903.29 +87.37 (+0.23%) Nasdaq
15,605.48 -52.34 (-0.33%) Bitcoin USD
57,928.59 -2,888.95 (-4.75%) CMC Crypto 200
1,270.61 -68.46 (-5.11%)
United Therapeutics Corporation (UTHR)
After hours:
| Previous close | 234.33 |
| Open | 243.00 |
| Bid | 254.77 x 100 |
| Ask | 255.21 x 100 |
| Day's range | 236.65 - 258.48 |
| 52-week range | 204.44 - 261.54 |
| Volume | |
| Avg. volume | 481,744 |
| Market cap | 11.32B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 12.89 |
| EPS (TTM) | 19.80 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 295.18 |
BenzingaLung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity
On Wednesday, United Therapeutics Corporation (NASDAQ:UTHR) reported first-quarter sales of $677.7 million, up 34% year over year, beating the consensus of $623.9 million. The company reported EPS of $6.17, up from $4.86 a year ago, surpassing the consensus of $5.56. “The first quarter of 2024 represents another quarter of record revenue and double-digit year-over-year revenue growth,” jointly said Martine Rothblatt, Chairperson and Chief Executive Officer and Michael Benkowitz, President and Ch
ZacksCompared to Estimates, United Therapeutics (UTHR) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- GuruFocus.com
United Therapeutics Surpasses Analyst Revenue Forecasts with Strong Q1 2024 Performance
Impressive Growth Driven by Tyvaso Product Line and Strategic Investments
